Tiotropium bromide inhalation powder: A review of its use in the management of chronic obstructive pulmonary disease

Drugs

Volumn 72, Issue 2, 2012, Pages 273-300

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Chronic obstructive pulmonary disease; Tiotropium bromide

Indexed keywords

ANTIINFLAMMATORY AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GELATINASE A; INDACATEROL; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; IPRATROPIUM BROMIDE; METHYLXANTHINE; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; EMBASE; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; HEART FAILURE; HUMAN; INHALATION; LUNG FUNCTION; MEDLINE; METHODOLOGY; MORTALITY; QUALITY OF LIFE; REVIEW; SYMPTOM; TREATMENT DURATION;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; COST-BENEFIT ANALYSIS; HUMANS; POWDERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES;

EID: 84856118942     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11208620-000000000-00000     Document Type: Review

References (101)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, managment, and prevention of chronic obstructive pulmonary disease (updated 2010) [online]. Available from URL: http://www.gold copd.org/uploads/users/files/GOLDReport-Apri112011.pdf [Accessed 2011 Oct 14]
2. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update fromtheAmerican College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011 Aug 2; 155 (3): 179-91
3. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000 Feb; 117 (2 Suppl.): 63-66S (Pubitemid 30111568)
4. Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999; 64 (6-7): 457-64 (Pubitemid 29066693)
5. Haddad E-B, Mak JCW, Barnes PJ. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 1994 May; 45: 899-907
6. Disse B, Reichl R, Speck G, et al. BA 679 BR, a novel longacting anticholinergic bronchodilator. Life Sci 1993; 52 (5-6): 537-44
7. Boehringer Ingelheim International GmbH. Spiriva 18 microgram inhalation powder, hard capsule: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/10039/SPC/ Spiriva+18+microgram+inhalation+powder%2c+hard+ capsule/[Accessed 2011 Sep 30]
8. Bateman ED, Rennard S, Barnes PJ, et al. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther 2009; 22 (6): 533-42
9. Takahashi T, Belvisi MG, Patel H, et al. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways.AmJRespirCritCareMed 1994Dec; 150 (6 Pt 1): 1640-5
10. Maesen FPV, Smeets JJ, Sledsens TJH, et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995 Sep; 8 (9): 1506-13
11. Calverley PMA, Lee A, Towse L, et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003 Oct; 58 (10): 855-60 (Pubitemid 37239232)
12. Cazzola M, Di Marco F, Santus P, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004; 17 (1): 35-9 (Pubitemid 37468407)
13. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161 (41): 1136-42 (Pubitemid 30243820)
14. van Noord JA, Smeets JJ, Custers FL, et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002 Apr; 19 (4): 639-44 (Pubitemid 34285160)
15. van Noord JA, Bantje TA, Eland ME, et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000 Apr; 55 (4): 289-94 (Pubitemid 30248798)
16. Casaburi R, Briggs DD, Donohue JF, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Chest 2000 Nov; 118 (5): 1294-302
17. Celli B, ZuWallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003 Nov; 124 (5): 1743-8 (Pubitemid 37433567)
18. O'Donnell DE, Flü ge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004 Jun; 23 (6): 832-40 (Pubitemid 38807355)
19. Verkindre C, Bart F, Aguilaniu B, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006; 73 (4): 420-7
20. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005 Sep; 128 (3): 1168-78 (Pubitemid 41324392)
21. Berton DC, Reis M, Siqueira ACB, et al. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respir Med 2010 Sep; 104 (9): 1288-96
22. Bé dard M-E, Brouillard C, Pepin V, et al. Tiotropium improves walking endurance in chronic obstructive pulmonary disease. Eur Respir J. Epub 2011 Jun 23
23. Legg D, Cooper CB, Celli B, et al. Treadmill endurance during 2 years treatment with tiotropium in patients with COPD [abstract]. 107th International Conference of the American Thoracic Society; 2011 May 13-18; Denver (CO)
24. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005 Mar; 127 (3): 809-17 (Pubitemid 40775509)
25. Kesten S, Casaburi R, Kukafka D, et al. Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis 2008; 3 (1): 127-36 (Pubitemid 351523725)
26. Ambrosino N, Foglio K, Balzano G, et al. Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance. Int J Chron Obstruct Pulmon Dis 2008; 3 (4): 771-80
27. Incorvaia C, Riario-Sforza GG, Pravettoni C, et al. Impairment of small airways in COPD patients with frequent exacerbations and effects of treatment with tiotropium. Int J Chron Obstruct Pulmon Dis 2008; 3 (1): 123-6 (Pubitemid 351523724)
28. Incorvaia C, Riario-Sforza GG, Pravettoni C, et al. Effects of replacing oxitropium with tiotropium on pulmonary function in patients with COPD: a randomized study. Respir Med 2007 Mar; 101 (3): 476-80 (Pubitemid 46196333)
29. Asano K, Shikama Y, Shoji N, et al. Tiotropium bromide inhibits TGF-b-induced MMP production from lung fibroblasts by interfering with Smad and MAPK pathways in vitro. Int J Chron Obstruct Pulmon Dis 2010; 5: 277-86
30. Asano K, Shikama Y, Shibuya Y, et al. Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro. Int J Chron Obstruct Pulmon Dis 2008; 3 (4): 781-9
31. Powrie DJ, Wilkinson TMA, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007 Sep; 30 (3): 472-8 (Pubitemid 351182070)
32. Hasani A, Toms N, Agnew JE, et al. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 2004 May; 125 (5): 1726-34 (Pubitemid 38648404)
33. Covelli H, Bhattacharya S, Cassino C, et al. Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy 2005 Dec; 25 (12): 1708-18 (Pubitemid 41790093)
34. Boehringer Ingelheim International GmbH. Spiriva Handihaler (tiotropium bromide inhalation powder): US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/021395s033lbl.pdf [Accessed 2011 Sep 30]
35. Nakanishi T, Haruta T, Shirasaka Y, et al. Organic cation transporter-mediated renal secretion of ipratropium and tiotropium in rats and humans. Drug Metab Dispos 2011; 39 (1): 117-22
36. Tü rck D, Weber W, Sigmund R, et al. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. J Clin Pharmacol 2004 Feb; 44 (2): 163-72 (Pubitemid 38114315)
37. Chan CKN, Maltais F, Sigouin C, et al. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J 2007 Nov/Dec; 14 (8): 465-72 (Pubitemid 351255918)
38. Freeman D, Lee A, Price D. Efficacy and safety of tiotropium in COPD patients in primary care: the SPiRiva Usual CarE (SPRUCE) study. Respir Res 2007; 8: 45
39. Johansson G, Lindberg A, Romberg K, et al. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Respir J 2008 Sep; 17 (3): 169-75
40. Moita J, Bá rbara C, Cardoso J, et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther 2008; 21 (1): 146-51
41. Sciurba FC, Siafakas N, Troosters T, et al. The efficacy and safety of tiotropium HandiHaler, 18 mg, once daily plus PRN salbutamol in COPD subjects naive to maintenance therapy [abstract]. 107th International Conference of the American Thoracic Society; 2011 May 13-18; Denver (CO)
42. Briggs DD, Covelli H, Lapidus R, et al. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 2005; 18 (6): 397-404 (Pubitemid 41354265)
43. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122 (1): 47-55 (Pubitemid 34754142)
44. Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011 Oct; 38 (4): 797-803
45. Rabe KF, Timmer W, Sagkriotis A, et al. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008 Aug; 134 (2): 255-62
46. Tashkin DP, Pearle J, Iezzoni D, et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009 Feb; 6 (1): 17-25
47. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009 Oct 15; 180 (8): 741-50
48. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. NEngl J Med 2008 Oct 9; 359 (15): 1543-54
49. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005 Sep 6; 143 (5): 317-26
50. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011 Mar 24; 364 (12): 1093-103
51. Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008 Jan 1; 177 (1): 19-26
52. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007 Apr 17; 146 (8): 545-55 (Pubitemid 351650535)
53. Tonnel A-B, Perez T, Grosbois J-M, et al. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis 2008; 3 (2): 301-10 (Pubitemid 352037890)
54. Center for Drug Evaluation and Research. Application number: 21-396. Medical review(s) [online]. Available fromURL: http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2004/21-395.pdf-Spiriva-Medr-P1.pdf [Accessed 2011 Oct 4]
55. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002 Feb; 19 (2): 217-24 (Pubitemid 34162820)
56. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003 May; 58 (5): 399-404 (Pubitemid 36560942)
57. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002 Feb; 19 (2): 209-16 (Pubitemid 34162819)
58. Boehringer Ingelheim Pharmaceuticals. Trial comparing tiotropium inhalation capsules vs placebo in chronic obstructive pulmonary disease (COPD) [ClinicalTrials.gov identifier NCT00523991]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Oct 18]
59. Adams SG, Anzueto A, Briggs DD, et al. Evaluation of withdrawal of maintenance tiotropium in COPD. Respir Med 2009 Oct; 103 (10): 1415-20
60. Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003 Sep; 97 (9): 1014-20 (Pubitemid 37098766)
61. Tashkin DP, Varghese ST. Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender. Pulm Pharmacol Ther 2011 Feb; 24 (1): 147-52
62. Tashkin D, Celli B, Kesten S, et al. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir Med 2010 Oct; 104 (10): 1495-504
63. Tashkin DP, Celli B, Kesten S, et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2010 Feb; 35 (2): 287-94
64. Fukuchi Y, Fernandez L, Kuo H-P, et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology 2011 Jul; 16 (5): 825-35
65. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009 Oct 3; 374 (9696): 1171-8
66. Morice AH, Celli B, Kesten S, et al. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med 2010 Nov; 104 (11): 1659-67
67. Troosters T, Celli B, Lystig T, et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010 Jul; 36 (1): 65-73
68. Cooper CB, Anzueto A, Decramer M, et al. Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials. Int J Chron Obstruct Pulmon Dis 2011; 6: 269-75
69. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006 Mar; 27 (3): 547-55 (Pubitemid 43372529)
70. Beeh KM, Vogelmeier C, Rutten-van Mö lkem MPHH, et al. Tiotropiumvs salmeterol inGOLDII andMaintenancena? ̈ve COPD patients: subgroup analyses of POET-COPD-trial [abstract no. P251]. 21stAnnualCongress of the European Respiratory Society; 2011 Sep 24-28; Amsterdam
71. Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009 Nov 15; 180 (10): 948-55
72. Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, et al. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med 2009 Oct; 103 (10): 1421-9
73. Kesten S, Celli B, Decramer M, et al. Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis 2009; 4: 397-409
74. Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010 Jan; 137 (1): 20-30
75. Calverley PMA, Stockley RA, Seemungal TA, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011 Mar; 139 (3): 505-12
76. US Food and Drug Administration. Early communication about an ongoing safety review of tiotropium (marketed as Spiriva HandiHaler) [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/DrugSafety InformationforHeathcareProfessionals/ucm070651.htm [Accessed 2011 Oct 13]
77. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008 Sep 24; 300 (12): 1439-50
78. Gani R, Griffin J, Kelly S, et al. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Prim Care Respir J 2010 Mar; 19 (1): 68-74
79. Maniadakis N, Tzanakis N, Fragoulakis V, et al. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Curr Med Res Opin 2006 Aug; 22 (8): 1599-607 (Pubitemid 44297438)
80. Naik S, Kamal KM, Keys PA, et al. Evaluating the costeffectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease. Clin Outcomes Res 2010; 2 (1): 25-36
81. Rutten-van Mö lkenMPMH, Oostenbrink JB,MiravitllesM, et al. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007 Jun; 8 (2): 123-35
82. Oostenbrink JB, Rutten-van Mö lken MPMH, Monz BU, et al. Probabilistic Markov model to assess the costeffectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005 Jan-Feb; 8 (1): 32-46 (Pubitemid 40293639)
83. Rennard SI, AndersonW, ZuWallack R, et al. Use of a longacting inhaled b2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 Apr; 163 (5): 1087-92 (Pubitemid 32378441)
84. Mittmann N, Hernandez P, Mellströ m C, et al. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives. Pharmacoeconomics 2011 May 1; 29 (5): 403-14
85. Center for Drug Evaluation and Research. Approval letter: NDA 21-395 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/ appletter/2004/21395ltr.pdf [Accessed 2011 Nov 30]
86. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994 Nov 16; 272 (19): 1497-505
87. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008 Aug 15; 178 (4): 332-8
88. Decramer M, Molenberghs G, Liu D, et al. Premature discontinuation during the UPLIFT study. Respir Med 2011 Oct; 105 (10): 1523-30
89. Tashkin DP. Preventing and managing exacerbations in COPD: critical appraisal of the role of tiotropium. Int J Chron Obstruct Pulmon Dis 2010; 5: 41-53
90. Rabe KF. Anticholinergic drugs for the treatment of COPD are safe: are they? Chest 2010 Jan; 137 (1): 1-3
91. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002 Aug 1; 166 (3): 333-9 (Pubitemid 34864422)
92. Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008 Sep 16; 149 (6): 380-90
93. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium: the FDA's conclusions. N Engl J Med 2010 Sep 16; 363 (12): 1097-9
94. Lanes S,Golisch W, Mikl J. Ipratropium and lung health study [letter]. Am J Respir Crit Care Med 2003 Mar 1; 167 (5): 801
95. Reilly JJ. COPD and declining FEV1: time to divide and conquer? N Engl J Med 2008 Oct 9; 359 (15): 1616-8
96. Singh S, Loke YK, Enright PL, et al. Mortality associatedwith tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011; 342: d3215
97. Disse E, Metzdorf N, Martin A, et al. Mortality associated with tiotropium mist inhaler? A critical appraisal of the authors' selection and use of previously communicated tiotropium Respimat data [online]. Available from URL: http://www.bmj.com/content/342/bmj.d3215?tab=responses [Accessed 2011 Nov 29]
98. Boehringer Ingelheim Pharmaceuticals. Comparison of tiotropium in the HandhiHaler versus the Respimat in chronic obstructive pulmonary disease [ClinicalTrials.gov identifier NCT01126437]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Oct 14]
99. Boehringer Ingelheim GmbH. Boehringer Ingelheim/Pfizer position regarding the recent publication by Singh et al. in the British Medical Journal, June 15, 2011 [media release]. Available from URL: http://www.boehringer-ingelheim. com/news/news-releases/press-releases/2011/15-june-2011-copd.html [Accessed 2011 Oct 14]
100. Cazzola M, Calzetta L, Matera MG. The cardiovascular risk of tiotropium: is it real? Expert Opin Drug Saf 2010 Sep; 9 (5): 783-92
101. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010 Oct 28; 363 (18): 1715-26